5369-00-6
5369-00-6
Chemical Structure
QX-222 chloride
- CAS No.: 5369-00-6
- Formula:C13H21ClN2O
- Molecular Weight:256.77
IUPAC Name: 2-((2,6-dimethylphenyl)amino)-N,N,N-trimethyl-2-oxoethan-1-aminium chloride
InChIKey: WFKXSWWTOZBDME-UHFFFAOYSA-N
SMILES: O=C(NC1=C(C)C=CC=C1C)C[N+](C)(C)C.[Cl-]
Biological Activity: QX-222 chloride, a trimethyl analogue of Lignocaine (HY-B0185), is a potent Na+ channel blocker[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
QX-222 chloride | 96.31% | QX-222 chloride, a trimethyl analogue of Lignocaine (HY-B0185), is a potent Na+ channel blocker. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
QX-222 chloride (Standard) | ≥98% | QX-222 (chloride) (Standard) is the analytical standard of QX-222 (chloride) (HY-101362). This product is intended for research and analytical applications. QX-222 chloride, a trimethyl analogue of Lignocaine (HY-B0185), is a potent Na+ channel blocker. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
QX-314 bromide (Standard) | ≥98% | QX-314 (bromide) (Standard) is the analytical standard of QX-314 (bromide) (HY-101350). This product is intended for research and analytical applications. QX-314 bromide is a membrane-impermeable permanently charged sodium channel blocker. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lidocaine methiodide | Lidocaine methiodide (Methyllidocaine iodide) is a potent antiarrythmic agent, and is a derivative of Lidocaine (HY-B0185). Lidocaine methiodide can be used for the research of ventricular arrhythmias produced by coronary occlusion. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
QX-314 chloride | 99.96% | QX-314 chloride is a membrane-impermeable permanently charged sodium channel blocker. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Antiarrhythmic agent-3 | Antiarrhythmic agent-3 is an antiarrhythmic drug with the activity of enhancing antiarrhythmic efficacy and improving inhibition index. The antiarrhythmic effect of antiarrhythmic agent-3 is related to its hydrophobicity (log P). The central nervous system toxicity of antiarrhythmic agent-3 is related to the combined effect of its hydrophobicity and acid constant (pKa). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lignocaine N-oxide | 99.92% | Lignocaine N-oxide (Lidocaine N-oxide) is a hypoxia-activated prodrug of lidocaine (HY-B0185). Lignocaine N-oxide exerts exactly the same sodium current-blocking effect as lidocaine only when it is converted to lidocaine under ischemic conditions. Lignocaine N-oxide possesses antiarrhythmic activity against ischemia-induced ventricular fibrillation. Lignocaine N-oxide can be used in studies related to ischemia-induced ventricular fibrillation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lidocaine hydrochloride | 99.84% | Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lidocaine hydrochloride hydrate (Standard) | ≥98% | Lidocaine (hydrochloride hydrate) (Standard) is the analytical standard of Lidocaine (hydrochloride hydrate). This product is intended for research and analytical applications. Lidocaine (Lignocaine) hydrochloride hydrate inhibits sodium channels involving complex voltage and using dependence. Lidocaine hydrochloride hydrate decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride hydrate is an amide derivative and has potential for the research of ventricular arrhythmia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lidocaine (Standard) | 99.97% | Lidocaine (Standard) is the analytical standard of Lidocaine. This product is intended for research and analytical applications. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence. Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Monoethylglycinexylidide hydrochloride | 98.82% | Monoethylglycinexylidide hydrochloride (MEGX hydrochloride; Norlidocaine hydrochloride) is the major metabolite of Lidocaine (HY-B0185), produced via oxidative metabolism by cytochrome P-450 enzymes in the liver. Monoethylglycinexylidide hydrochloride can be used for research on liver cirrhosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride | N-(2,6-dimethylphenyl)-2-(ethyl(methyl)amino)acetamide hydrochloride is an impurity in the sodium channel inhibitor Lidocaine (HY-B0185). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. A Sunami, et al. A critical residue for isoform difference in tetrodotoxin affinity is a molecular determinant of the external access path for local anesthetics in the cardiac sodium channel. Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2326-31. [Content Brief]
- [2]. Qingmin Chen, et al. Differential blockade of nerve injury-induced thermal and tactile hypersensitivity by systemically administered brain-penetrating and peripherally restricted local anesthetics. J Pain. 2004 Jun;5(5):281-9. [Content Brief]
- [3]. J A Flatman, et al. Reversibility of Ia EPSP investigated with intracellularly iontophoresed QX-222. J Neurophysiol. 1982 Aug;48(2):419-30. [Content Brief]
